BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 8912347)

  • 1. An immunohistochemical study of p53 protein in ovarian mucinous neoplasms.
    Teh M; Lee YS
    Pathology; 1996 Aug; 28(3):217-9. PubMed ID: 8912347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic disparity between morphologically benign cysts contiguous to ovarian carcinomas and solitary cystadenomas.
    Zheng J; Benedict WF; Xu HJ; Hu SX; Kim TM; Velicescu M; Wan M; Cofer KF; Dubeau L
    J Natl Cancer Inst; 1995 Aug; 87(15):1146-53. PubMed ID: 7674319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MDM2 Expression in Serous and Mucinous Epithelial Tumours of the Ovary.
    Abdelaal SE; Habib FM; El Din AA; Gabal SM; Hassan NS; Ibrahim NA
    Asian Pac J Cancer Prev; 2016; 17(7):3295-300. PubMed ID: 27509966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of p21WAF1/CIP1 and MDM2 characterizes serous borderline ovarian tumors.
    Palazzo JP; Monzon F; Burke M; Hyslop T; Dunton C; Barusevicius A; Capuzzi D; Kovatich AJ
    Hum Pathol; 2000 Jun; 31(6):698-704. PubMed ID: 10872663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p14 expression differences in ovarian benign, borderline and malignant epithelial tumors.
    Cabral VD; Cerski MR; Sa Brito IT; Kliemann LM
    J Ovarian Res; 2016 Oct; 9(1):69. PubMed ID: 27770808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors.
    Berchuck A; Kohler MF; Hopkins MP; Humphrey PA; Robboy SJ; Rodriguez GC; Soper JT; Clarke-Pearson DL; Bast RC
    Gynecol Oncol; 1994 Feb; 52(2):232-6. PubMed ID: 7508877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The frequency and prognostic role of P53 and P16 immunoexpression in primary ovarian mucinous tumors.
    Nergiz D; Yıldırım HT; Süren D; Sadullahoğlu C; Yıldırım Ş; Üreyen I
    Ann Diagn Pathol; 2024 Oct; 72():152330. PubMed ID: 38772285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of pro-apoptotic (p53, p21, bax, bak and fas) and anti-apoptotic (bcl-2 and bcl-x) proteins in serous versus mucinous borderline ovarian tumours.
    Fauvet R; Dufournet C; Poncelet C; Uzan C; Hugol D; Daraï E
    J Surg Oncol; 2005 Dec; 92(4):337-43. PubMed ID: 16299808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The immunohistochemical expression of p53 and Ki67 in ovarian epithelial borderline tumors. Correlation with clinicopathological factors.
    Giurgea LN; Ungureanu C; Mihailovici MS
    Rom J Morphol Embryol; 2012; 53(4):967-73. PubMed ID: 23303020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
    Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
    Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human papilloma virus (HPV) status, p16INK4a, and p53 overexpression in epithelial malignant and borderline ovarian neoplasms.
    Giordano G; Azzoni C; D'Adda T; Rocco A; Gnetti L; Froio E; Merisio C; Melpignano M
    Pathol Res Pract; 2008; 204(3):163-74. PubMed ID: 18180113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P53, bcl-2, ki-67 li (labeling index) status in benign, proliferative, and malignant ovarian surface epithelial neoplasms.
    Gursan N; Sipal S; Calik M; Gundogdu C
    Eurasian J Med; 2009 Apr; 41(1):10-4. PubMed ID: 25610057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identical, unique p53 mutations in a primary ovarian mucinous adenocarcinoma and a synchronous contralateral ovarian mucinous tumor of low malignant potential suggest a common clonal origin.
    Werness BA; DiCioccio RA; Piver MS
    Hum Pathol; 1997 May; 28(5):626-30. PubMed ID: 9158713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p63 expression in epithelial ovarian tumors.
    Poli Neto OB; Candido Dos Reis FJ; Zambelli Ramalho LN; Nogueira AA; de Andrade JM
    Int J Gynecol Cancer; 2006; 16(1):152-5. PubMed ID: 16445626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EXPRESION OF P53 IN OVARAN EPITHELIAL TUMOURS AND ITS CORRELATION WITH HISTOPATHOLOGICAL PARAMETERS.
    Abbasi F; Esmaili A; Yekta Z; Saffarifard A
    J Ayub Med Coll Abbottabad; 2016; 28(1):3-6. PubMed ID: 27323551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53 protein expression and DNA ploidy in cystic tumors of the pancreas.
    Fléjou JF; Boulange B; Bernades P; Belghiti J; Hénin D
    Pancreas; 1996 Oct; 13(3):247-52. PubMed ID: 8884845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of glucose transporter protein 1 and p63 in serous ovarian tumor.
    Cai Y; Zhai JJ; Feng BB; Duan XZ; He XJ
    J Obstet Gynaecol Res; 2014 Jul; 40(7):1925-30. PubMed ID: 25056472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterogeneous distribution of K-ras-mutated epithelia in mucinous ovarian tumors with special reference to histopathology.
    Mandai M; Konishi I; Kuroda H; Komatsu T; Yamamoto S; Nanbu K; Matsushita K; Fukumoto M; Yamabe H; Mori T
    Hum Pathol; 1998 Jan; 29(1):34-40. PubMed ID: 9445131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological study of metallothionein immunohistochemical expression, in benign, borderline and malignant ovarian epithelial tumors.
    Zagorianakou N; Stefanou D; Makrydimas G; Zagorianakou P; Briasoulis E; Karavasilis V; Pavlidis N; Agnantis NJ
    Histol Histopathol; 2006 Apr; 21(4):341-7. PubMed ID: 16437378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of p53 and MIB1 expression in benign and borderline areas of ovarian serous tumors.
    Marcelli AR; Demopoulos RI; Goswami S; Mittal KR
    Int J Gynecol Pathol; 1996 Jan; 15(1):39-44. PubMed ID: 8852445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.